OPPI Chief Vaidheesh On Burning Industry Issues In India
Executive Summary
The Organization of Pharmaceutical Producers of India (OPPI) essentially reflects the views of foreign firms in the country. In an interview with Scrip, OPPI’s new chief and GSK vice president (South Asia) and managing director (India) Annaswamy Vaidheesh shares the industry body’s take on several critical issues including the Indian government’s push for generic medicines and why the effective contract manufacturing model should not be “disrupted” by proposed policy reform.
You may also be interested in...
Pharma Counters India Competition Commission On ‘Market-Distorting’ Practices
A note by the Competition Commission of India has put the spotlight back on certain pharma industry practices that are seen as triggering non-competitive market outcomes. Pharma has called into question certain claims of the CCI, with some experts suggesting that the regulator may have also exceeded its remit.
Pharma Counters India Competition Commission On ‘Market-Distorting’ Practices
A note by the Competition Commission of India has put the spotlight back on certain pharma industry practices that are seen as triggering non-competitive market outcomes. Pharma has called into question certain claims of the CCI, with some experts suggesting that the regulator may have also exceeded its remit.
GSK Puts Tail End Brands On The Block In India
GlaxoSmithKline is believed to be keen to divest close to a dozen tail-end brands across therapy groups including anti-infectives and dermatology in India as it tweaks its portfolio to focus on sustained profitable growth.